SCHEMBL3967079

SCHEMBL3967079

CCOC(=O)C=CO[Si](C)(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 4/20 0.52
MAPT P10636 5/20 0.43
ATM Q13315 1/20 0.42
NPSR1 Q6W5P4 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
ALDH1A1 P00352 3/20 0.39
TTR P02766 1/20 0.38
DPP4 P27487 1/20 0.38
LMNA P02545 3/20 0.36
HTT P42858 1/20 0.36
TRPM8 Q7Z2W7 1/20 0.36
MDM2 Q00987 1/20 0.36
HSD17B10 Q99714 1/20 0.36
CYP3A4 P08684 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3966610 1.00 HCAR2 (0.52) HCAR2MAPTATMNPSR1CA12
SCHEMBL20396202 0.86 HCAR2 (0.57) HCAR2MAPTATMNPSR1ALDH1A1
SCHEMBL28631104 0.77 ATM (0.37) HCAR2ATM
SCHEMBL9718851 0.77 ATM (0.33) HCAR2ATM
SCHEMBL6894763 0.77 HCAR2 (0.59) HCAR2MAPTATMNPSR1CA12
SCHEMBL9709153 0.77 HCAR2 (0.59) HCAR2MAPTATMNPSR1CA12
Diethyl Maleate SCHEMBL42602 0.77 HCAR2 (0.80) HCAR2MAPTATMNPSR1CA12
Diethyl Maleate SCHEMBL60423 0.77 HCAR2 (0.80) HCAR2MAPTATMNPSR1CA12
Diethyl Maleate SCHEMBL43033 0.77 HCAR2 (0.80) HCAR2MAPTATMNPSR1CA12
Diethyl Maleate SCHEMBL2015895 0.77 HCAR2 (0.80) HCAR2MAPTATMNPSR1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7560550-B2 Method for the production of OH protected[4-(2.6-diamino-9H-purine-9-yl)-1.3-dioxolane-2-yl]methanol derivatives RFS PHARMA, LLC (US) 2009-07-14 US claimed
EP-1814939-A4 ULTRAVIOLET LIGHT (UV) ABSORBING COMPOUNDS AND COMPOSITIONS CONTAINING UV ABSORBING COMPOUNDS MILLIKEN & CO (US) 2009-07-29 EP disclosed
US-7560550-B2 Method for the production of OH protected[4-(2.6-diamino-9H-purine-9-yl)-1.3-dioxolane-2-yl]methanol derivatives RFS PHARMA, LLC (US) 2009-07-14 US disclosed
US-7381762-B2 Ultraviolet light (UV) absorbing compounds and compositions containing UV absorbing compounds MILLIKEN & COMPANY (US) 2008-06-03 US disclosed
EP-1648894-B1 METHOD FOR THE PRODUCTION OF OH PROTECTED [4-(2.6-DIAMINO-9H-PURINE-9-YL)- 1.3-DIOXOLANE-2-YL]METHANOL DERIVATIVES WACKER CHEMIE AG (DE) 2007-09-12 EP disclosed
EP-1814939-A2 ULTRAVIOLET LIGHT (UV) ABSORBING COMPOUNDS AND COMPOSITIONS CONTAINING UV ABSORBING COMPOUNDS Milliken&Company (US) 2007-08-08 EP disclosed
US-20060211855-A1 Method for the production of oh protected{4-(2.6-diamino-9h-purine-9-yl)-1.3-dioxolane-2-yl] methanol derivatives WACKER CHEMIE AG (DE) 2006-09-21 US disclosed
CN-1816532-A Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents SCHERING AG (DE) 2006-08-09 CN disclosed
EP-1648894-A1 METHOD FOR THE PRODUCTION OF OH PROTECTED [4-(2.6-DIAMINO-9H-PURINE-9-YL)- 1.3-DIOXOLANE-2-YL]METHANOL DERIVATIVES Wacker Chemie AG (DE) 2006-04-26 EP disclosed
WO-2006023687-A2 ULTRAVIOLET LIGHT (UV) ABSORBING COMPOUNDS AND COMPOSITIONS CONTAINING UV ABSORBING COMPOUNDS MILLIKEN & COMPANY (US) 2006-03-02 WO disclosed
US-20060041038-A1 Ultraviolet light (UV) absorbing compounds and compositions containing UV absorbing compounds MILLIKEN & COMPANY 2006-02-23 US disclosed
WO-2005012302-A1 METHOD FOR THE PRODUCTION OF OH PROTECTED [4-(2.6-DIAMINO-9H-PURINE-9-YL)- 1.3-DIOXOLANE-2-YL]METHANOL DERIVATIVES WACKER CHEMIE AG (DE) 2005-02-10 WO disclosed
EP-1492771-A1 QUINOLINE AND ISOQUINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS SCHERING AKTIENGESELLSCHAFT (DE) 2005-01-05 EP disclosed
WO-2003082827-A1 QUINOLINE AND ISOQUINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS SCHERING AKTIENGESELLSCHAFT (DE) 2003-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211855-A1 Method for the production of oh protected{4-(2.6-diamino-9h-purine-9-yl)-1.3-dioxolane-2-yl] methanol derivatives FUT6, FUT5, ST6GAL1 HCAR2 793/4885MAPT 4596/4885ATM 3884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.